Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of giving tanespimycin together
with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for
lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin,
work in different ways to stop cancer cells from dividing so they stop growing or die.
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their
growth. It may also increase the effectiveness of tanespimycin by making cancer cells more
sensitive to the drug. Combining tanespimycin with bortezomib may kill more cancer cells.